Market Wage Study Sample Clauses

Market Wage Study. ‌ 6.4.1 Commencing no later than February 15, 2024, the parties shall convene a pre- negotiations process to identify “comparable” employers, survey classifications, and salary and benefit data to be collected in a market wage survey. If the parties agree on all of the components of the study, the County shall collect the data, complete the market wage study, and provide it to the Association as soon as administratively feasible with a target date of April 15, 2024. The County shall meet with representatives of the Association periodically during the conduct of the study to review data that is being collected. If by April 1, 2024 the parties are unable to agree on all of the components of the market wage study, the County shall complete a market wage study and provide it to the Association with a target date of May 1, 2024. This study will include a chart showing the standing of the SDSA bargaining unit based on selected comparable employers, survey classifications, and total compensation elements selected by the County. Any disagreements between the parties on the data factors included in the market wage study shall be addressed in successor negotiations. The County survey shall include at a minimum the following five employers: Santa Xxxxxxx County, Monterey County, Santa Xxxx County, Sonoma County, and Napa County. 1 The Prevailing Wage Ordinance provides in pertinent part: “prevailing salaries or wages shall be determined by negotiations between the County’s employer representatives and the recognized employee organization(s).” 6.4.2 The Association may also conduct a market wage study and provide it to the County with a target date of May 1, 2024 for use in successor contract negotiations. For purpose of opening proposals covering the time period commencing January 1, 2025, the content of the wage studies described above shall not limit the ability of either party to make such wage proposals or to present such additional data as they see fit during the course of successor contract negotiations.
Sample 1See All (4)
AutoNDA by SimpleDocs
Market Wage Study. 8.5.1 Commencing no later than August 1, 2017, the parties shall convene a pre- negotiations process to identify “comparable” employers, survey classifications, and salary and benefit data to be collected in a market wage survey. If the parties agree on all of the components of the study, the County shall collect the data, complete the market wage study, and provide it to the Association as soon as administratively feasible with a target 8.5.2 If by September 1, 2017 the parties are unable to agree on all of the components of the market wage study, the County shall complete a market wage study and provide it to the Association with a target date of November 1, 2017. This study will include a chart showing the standing of the SLOCEA bargaining unit based on selected comparable employers, survey classifications, and total compensation elements selected by the County. Any disagreements between the parties on the data factors included in the market wage study shall be addressed in successor negotiations. 8.5.3 The Association may also conduct a market wage study and provide it to the County with a target date of November 1, 2017 for use in successor contract negotiations. 8.5.4 For purpose of opening proposals covering the time period commencing July 1, 2018, the content of the wage studies described above shall not limit the ability of either party to make such wage proposals and present additional data as they see fit during the course of successor contract negotiations.
Sample 1Sample 2Sample 3
Market Wage Study. ‌ Commencing no later than May 1, of the final year of the agreement the parties shall convene a pre-negotiations process to identify “comparable” employers, survey classifications, and salary and benefit data to be collected in a compensation survey. If the parties agree on all of the components of the study, the County shall collect the data, complete the survey, and provide it to the Association as soon as administratively feasible with a target date of July 1, of the final year of this agreement. The County shall meet with representatives of the Association periodically during the conduct of the study to review data that is being collected. If by June 1, of the final year of this agreement the parties are unable to agree on all of the components of the market wage study, the County shall provide its data and analysis to the Association with a target date of July 1, of the final year of this agreement. The Association may also conduct a compensation study and provide it to the County for use in successor contract negotiations. For purpose of opening proposals covering the time period commencing January 1, 2023, the content of the compensation studies described above shall not limit the ability of either party to make such wage proposals and present additional data as they see fit during the course of successor contract negotiations.
Sample 1Sample 2
Market Wage Study. ‌ The parties agree to conduct a compensation study and attempt to agree upon
Sample 1Sample 2
Market Wage Study. 6.3.1 Commencing no later than May 1, 2019, the parties shall convene a pre- negotiations process to identify “comparable” employers, survey classifications, and salary and benefit data to be collected in a market wage survey. If the parties agree on all of the components of the study, the County shall collect the data, complete the market wage study, and provide it to the Association as soon as administratively feasible with a target date of July 1, 2019. The County shall meet with representatives of the Association periodically during the conduct of the study to review data that is being collected. 6.3.2 If by June 1, 2019 the parties are unable to agree on all of the components of the market wage study, the County shall complete a market wage study and provide it to the Association with a target date of July 1, 2019. This study will include a chart showing the standing of the DSA bargaining unit based on selected comparable employers, survey classifications, and compensation elements selected by the County. Any disagreement between the parties on the data included in the market wage study shall be addressed in successor negotiations. 6.3.3 The Association may also conduct a market wage study and provide it to the County with a target date of July 1, 2019 for use in successor contract negotiations. 6.3.4 For purpose of opening proposals covering the time period commencing January 1, 2020, the content of the wage studies described above shall not limit the ability of either party to make such wage proposals and present additional data as they see fit during the course of successor contract negotiations. 6.3.5 Wage and benefit data shall be collected from the following employers for comparable classifications: Local Employers: City of San Xxxx Obispo, State of California, and Cal Poly California Counties: Fresno, Xxxx, Monterey, Santa Barbara, Ventura, El Dorado, Sonoma, Placer, and Santa Xxxx Private sector employer data from within San Xxxx Obispo County where determined appropriate by the County
Sample 1Sample 2
Market Wage Study. ‌ 6.2.1 Commencing no later than February 15, 2016, the parties shall convene a pre- negotiations process to identify “comparable” employers, survey classifications, and salary and benefit data to be collected in a market wage survey. If the parties agree on all of the components of the study, the County shall collect the data, complete the market 6.2.1.1 The following data points shall be collected 6.2.2 The Association may also conduct a market wage study and provide it to the County with a target date of May 1, 2016 for use in successor contract negotiations.
Sample 1
Market Wage Study. 8.2.1 The parties agree to conduct a compensation study and attempt to agree upon (1) comparable employers, (2) what components of total compensation shall be measured, and (3) how to value a particular component of total compensation that will be measured. By entering into this Agreement, neither party waives any right it has or may have to contest in any appropriate forum the manner in which total compensation has been or will be calculated. 8.2.2 The parties’ respective proposals regarding the above factors and regarding compensation adjustments shall be completed and exchanged on or before March 1 of the final year of this Agreement.
Sample 1
AutoNDA by SimpleDocs
Market Wage Study. ‌ 6.2.1 Commencing no later than February 15, 2016, the parties shall convene a pre- negotiations process to identify “comparable” employers, survey classifications, and salary and benefit data to be collected in a market wage survey. If the parties agree on all of the components of the study, the County shall collect the data, complete the market wage study, and provide it to the Association as soon as administratively feasible with a target date of April 15, 2016. The County shall meet with representatives of the 6.2.1.1 The following data points shall be collected 6.2.2 The Association may also conduct a market wage study and provide it to the County with a target date of May 1, 2016 for use in successor contract negotiations.
Sample 1

Related to Market Wage Study

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Clinical 1.1 Provides comprehensive evidence based nursing care and individual case management to a specific group of patients/clients including assessment, intervention and evaluation. 1.2 Undertakes clinical shifts at the direction of senior staff and the Nursing Director including participation on the on-call/after-hours/weekend roster if required. 1.3 Responsible and accountable for patient safety and quality of care through planning, coordinating, performing, facilitating, and evaluating the delivery of patient care relating to a particular group of patients, clients or staff in the practice setting. 1.4 Monitors, reviews and reports upon the standard of nursing practice to ensure that colleagues are working within the scope of nursing practice, following appropriate clinical pathways, policies, procedures and adopting a risk management approach in patient care delivery. 1.5 Participates in xxxx rounds/case conferences as appropriate. 1.6 Educates patients/carers in post discharge management and organises discharge summaries/referrals to other services, as appropriate. 1.7 Supports and liaises with patients, carers, colleagues, medical, nursing, allied health, support staff, external agencies and the private sector to provide coordinated multidisciplinary care. 1.8 Completes clinical documentation and undertakes other administrative/management tasks as required. 1.9 Participates in departmental and other meetings as required to meet organisational and service objectives. 1.10 Develops and seeks to implement change utilising expert clinical knowledge through research and evidence based best practice. 1.11 Monitors and maintains availability of consumable stock. 1.12 Complies with and demonstrates a positive commitment to Regulations, Acts and Policies relevant to nursing including the Code of Ethics for Nurses in Australia, the Code of Conduct for Nurses in Australia, the National Competency Standards for the Registered Nurse and the Poisons Act 2014 and Medicines and Poisons Regulations 2016. 1.13 Promotes and participates in team building and decision making. 1.14 Responsible for the clinical supervision of nurses at Level 1 and/or Enrolled Nurses/ Assistants in Nursing under their supervision.

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Study Population ‌ Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).

  • Trials The Ship shall run the following test and trials: (1) Harbour Acceptance Tests, including setting to work of the various equipment;

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Licensed Product The term “Licensed Product” shall mean any product (a) the manufacture, use, importation, sale or offer for sale of which would, in the absence of the license granted by this Agreement, infringe a Valid Claim of any of the Licensed Patent Rights, or (b) that is comprised of, utilizes or incorporates Licensed Biological Materials, or (c) that is discovered, developed or made using a Licensed Process.

  • Product Testing No later than [**] prior to a scheduled Delivery ARIAD US shall send to ARIAD SWISSCO the Delivery Documents for review. Following such review, unless within [**] of receipt of the Delivery Documents ARIAD SWISSCO gives written notice of rejection of the Product to be delivered, stating the reasons for such rejection, the Delivery shall proceed, and both Parties shall organize the same. Upon arrival at ARIAD SWISSCO nominated site it shall visually inspect the shipment of the Product to identify any damage to the external packaging. ARIAD SWISSCO may reject any shipment (or portion thereof) of the Product that is damaged by providing to ARIAD US reasonable evidence of damage within [**] after Delivery of such Product. If ARIAD SWISSCO does not so reject any shipment (or portion thereof) of the Product within [**] of Delivery of such Product, ARIAD SWISSCO shall be deemed to have accepted such shipment of the Product; provided, however, that in the case of the Product having any Latent Defect, ARIAD SWISSCO shall notify ARIAD US promptly once it becomes aware that a Product contains a Latent Defect and subsequently may reject such Product by giving written notice to ARIAD US of ARIAD SWISSCO’s rejection of such Product and shipping a representative sample of such Product or other evidence of Non-Conformance to ARIAD US within [**] after becoming aware of such Latent Defect, which notice shall include a description of the Latent Defect.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!